Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gproan combined hepatitis C + E VLP vaccine
- Development stage
- Preclinical
- Lead developer
- Gproan Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Gproan combined hepatitis C + E VLP vaccine is a bivalent vaccine candidate being developed by Gproan Biotech for the prevention of Hepatitis C and Hepatitis E infections. The vaccine utilizes virus-like particle (VLP) technology, which involves the assembly of viral proteins into structures that mimic the native virus but lack the viral genome, rendering them non-infectious. These VLPs are engineered to display antigens from both the Hepatitis C virus (HCV) and the Hepatitis E virus (HEV). The production process employs a baculovirus expression vector system (BEVS) within insect cell lines to ensure proper protein folding and assembly. This combined approach is designed to simplify immunization schedules and provide broad protection against two significant causes of viral hepatitis, particularly in endemic regions.
- Other names
- Combined hepatitis C + E virus-like particle vaccineGproan HCV/HEV VLP vaccine
02
Targets
HCV E2 (Hepatitis C virus envelope glycoprotein E2)HEV ORF2 (Hepatitis E virus capsid protein)
Beyond the preview
Go deeper on Gproan combined hepatitis C + E VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gproan combined hepatitis C + E VLP vaccine.